Title: Exisulind
CAS Registry Number: 59973-80-7
CAS Name: (1Z)-5-Fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic acid
Additional Names: cis-5-fluoro-2-methyl-1-(p-methylsulfonylbenzylidene)-3-acetic acid; sulindac sulfone
Manufacturers' Codes: FGN-1
Trademarks: Aptosyn (Cell Pathways)
Molecular Formula: C20H17FO4S
Molecular Weight: 372.41
Percent Composition: C 64.50%, H 4.60%, F 5.10%, O 17.18%, S 8.61%
Literature References: Sulfone metabolite of sulindac, q.v.; induces apoptosis of cancer cells. Identification as metabolite: H. B. Hucker et al., Drug Metab. Dispos. 1, 721 (1973). Prepn: H. Jones et al., J. Carbohydr. Nucleosides Nucleotides 3, 369 (1974). Antiproliferative effect vs colon cancer cells: L. J. Hixson et al., Cancer Epidemiol. Biomarkers Prev. 3, 433 (1994). HPLC determn in serum: M. Siluveru, J. T. Stewart, J. Chromatogr. B 673, 91 (1995); and clinical pharmacokinetics: G. F. Ray et al., J. Pharm. Biomed. Anal. 14, 213 (1995). Review of mechanism of action studies: D. J. Ahnen, Eur. J. Surg. Suppl. 582, 111-114 (1998).
Properties: mp 194-196°. [a]D -62° (c = 1 in CHCl3).
Melting point: mp 194-196°
Optical Rotation: [a]D -62° (c = 1 in CHCl3)
Therap-Cat: In treatment of colorectal polyps.
Exosurf? Factor IX Factor V Factor VII Factor VIII

Jmol-3D images Image 1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Exisulind is a drug used to treat cancer. It acts by inhibiting the enzyme cyclic guanosine monophosphate phosphodiesterase. Trademark by OSI Pharmaceuticals is Aptosyn. NCBI PubChem ID 5472495. Also listed as Sulindac sulfone which is a metabolic product of Sulindac (see).